Phenylketonuria
Phenylketonuria (PKU) is a rare autosomal recessive metabolic disorder characterized by a deficiency of the hepatic enzyme phenylalanine hydroxylase (PAH). This enzyme is crucial for the conversion of the essential amino acid phenylalanine to tyrosine. In the absence or significant reduction of PAH activity, phenylalanine accumulates in the blood and brain, leading to neurotoxic effects. The pathogenesis of PKU involves mutations in the PAH gene, resulting in impaired enzyme function and a subsequent rise in phenylalanine levels. Elevated phenylalanine disrupts normal brain development and myelination, leading to intellectual disability, seizures, behavioral problems, and psychiatric disorders if untreated. Additional health impacts include hypopigmentation due to decreased melanin synthesis, eczema, and a musty odor of the skin and urine resulting from phenylacetate accumulation. Early detection and intervention are critical to prevent irreversible neurological damage.
Classic PKU is the most severe form of the disease, resulting from near-complete or complete deficiency of phenylalanine hydroxylase activity. Individuals with classic PKU typically exhibit plasma phenylalanine concentrations greater than 1200 μmol/L without dietary restriction. If untreated, classic PKU leads to profound intellectual disability, microcephaly, behavioral disturbances, seizures, and severe developmental delays. Early and strict dietary management is essential to prevent these outcomes.
Mild PKU is characterized by partial PAH deficiency, with plasma phenylalanine levels ranging from approximately 600 to 1200 μmol/L. Individuals with mild PKU are at risk for neurocognitive impairment, but the clinical manifestations are generally less severe than in classic PKU. Some residual enzyme activity allows for greater dietary phenylalanine tolerance, and outcomes are favorable with appropriate treatment.
Mild hyperphenylalaninemia represents the mildest spectrum of PAH deficiency, with plasma phenylalanine concentrations between 120 and 600 μmol/L. Most individuals with this form do not develop clinical symptoms and may not require dietary intervention, though monitoring is recommended. The risk of neurotoxicity is significantly lower compared to classic or mild PKU.
This type encompasses disorders resulting from defects in the synthesis or recycling of tetrahydrobiopterin (BH4), an essential cofactor for PAH. BH4-deficient hyperphenylalaninemia may present with elevated phenylalanine levels and additional neurological symptoms due to impaired synthesis of neurotransmitters such as dopamine and serotonin. Management differs from classic PKU and may require BH4 supplementation and neurotransmitter precursors.
Phenylketonuria exhibits marked variability in prevalence depending on geographic region and ethnic background. Globally, the estimated incidence ranges from 1 in 10,000 to 1 in 15,000 live births, with higher frequencies observed in European populations and lower rates in individuals of African or East Asian descent. In the United States, the incidence is approximately 1 in 13,500 to 1 in 15,000 newborns. PKU is included in newborn screening programs in most developed countries, contributing to early diagnosis and improved outcomes. The carrier frequency for PAH gene mutations is estimated at 1 in 50 in populations of European ancestry. Advances in genetic testing and expanded screening have facilitated the identification of milder forms of hyperphenylalaninemia, influencing reported prevalence rates.
The diagnosis of phenylketonuria is established through a combination of newborn screening, biochemical testing, and molecular genetic analysis. Universal newborn screening involves measurement of blood phenylalanine concentration, typically using a dried blood spot collected 24 to 72 hours after birth. Elevated phenylalanine levels above the established threshold prompt confirmatory testing, which includes quantitative plasma amino acid analysis to assess phenylalanine and tyrosine concentrations. The diagnostic criteria for PKU are based on persistent elevation of plasma phenylalanine, with values exceeding 120 μmol/L indicating hyperphenylalaninemia and higher thresholds distinguishing classic and mild forms. Differential diagnosis includes exclusion of secondary causes of hyperphenylalaninemia, such as liver disease or other metabolic disorders. Molecular genetic testing of the PAH gene can confirm the diagnosis, identify specific mutations, and facilitate carrier detection and genetic counseling. In cases of suspected tetrahydrobiopterin (BH4) deficiency, additional tests such as urine pterin analysis, dihydropteridine reductase activity measurement, and BH4 loading tests are performed to guide appropriate management.
Pegvaliase is an enzyme substitution therapy approved for the treatment of phenylketonuria, functioning by enzymatically degrading excess phenylalanine in the blood and thereby reducing its neurotoxic effects in affected individuals. Sapropterin dihydrochloride, a synthetic form of tetrahydrobiopterin, acts as a pharmacological chaperone to enhance residual phenylalanine hydroxylase activity in responsive patients, leading to decreased blood phenylalanine concentrations and improved metabolic control.
| Structure | Generic Name | CAS Registry Number | Molecular Formula | Molecular Weight |
|---|---|---|---|---|
| pegvaliase (Rec INN); pegvaliase-pqpz | 1585984-95-7 | |||
 | dapropterin dihydrochloride; sapropterin dihydrochloride (Rec INNM; USAN) | 69056-38-8 | C9 H15 N5 O3 . 2 Cl H | 314.169 |
Make Order
Experimental Scheme
Implementation
Conclusion
